Company news

Frontier Biotechnologies Inc. Class A (SSE:688221) news

Frontier Biotechnologies Inc. Class A news releases on 6ix. Latest, Sep 30, 2026: "Frontier Biotechnologies Inc."Indicative Announcement on Change in Equity…

Frontier Biotechnologies Inc. Class A (SSE:688221) news

Press releases & updates

"Frontier Biotechnologies Inc."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% and 5% Thresholds

"Frontier Biotechnologies Inc."Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Working Capital

"Frontier Biotechnologies Inc."Announcement on Use of Temporarily Idle Raised Funds for Cash Management

"Frontier Biotechnologies Inc."Voluntary Disclosure Announcement on Obtaining Drug Registration Certificate for FB3002 Loxoprofen Sodium Patches

"Frontier Biotechnologies Inc."Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% and 5% Threshold

"Frontier Biotechnologies Inc."Announcement on Returning Idle Raised Funds Used to Temporarily Supplement Current Capital

"Frontier Biotechnologies Inc."Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2025 Annual Report

Announcement on Resolutions of the 2025 Annual General Meeting

Correction Announcement on Preliminary Earnings Estimate for 2025 and Earnings Preannouncement

Announcement on Changing the Disclosure Time of 2025 Annual Report and Report for Q1 2026

Announcement on Conducting Foreign Exchange Derivatives Trading Business

Announcement on Change of Scheduled Disclosure Time for Periodic Reports

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of FB7013 Injection

Announcement on Preliminary Earnings Estimate for 2025

Announcement on the Signing of an Authorization and License Agreement with GSK

Earnings Preannouncement for 2025

Announcement on Completing Industrial and Commercial Change Registration for Company Address Change and Issuance of New Business License

Announcement on Voluntary Disclosure of Acceptance Notice for the Clinical Trial Application for Domestic Production of Drugs of FB7013

Announcement on Resolutions of the 9th Meeting of the 4th Board of Directors

Announcement on Election of Employee Directors for the 4th Board of Directors

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Publicity Description and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on the List of Incentive Objects Initially Granted in the 2025 Restricted Stock Incentive Plan

Announcement on Resolutions of the 6th Meeting of the 4th Board of Supervisors

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Repayment of Previously Temporarily Used Raised Funds for Working Capital and Continued Use of Partial Idle Raised Funds to Temporarily Supplement Working Capital

Announcement on Changing Some Investment Projects Financed by Raised Funds

Announcement on Resolutions of the 3rd Meeting of the 4th Board of Supervisors

Announcement on Reply to the Regulatory Inquiry Letter on Information Disclosure of 2024 Annual Report

Announcement on Change of Sponsor Representative

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Signing the Supplementary Agreement and Passive Extension of Related Party Loans

Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and Convening the Q1 2025 Performance Briefing

Announcement on Preliminary Earnings Estimate for 2024

Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

Voluntary Disclosure Announcement on Approval of Phase II Clinical Trial for New Indication of Immune Reconstitution Insufficient of Aikening

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2024

Announcement on Resolution of the 18th Meeting of the 3rd Board of Supervisors

Announcement on the Renewal of Company Product Albuvirtide for Injection for Inclusion in the Catalogue of Drugs for Basic National Medical Insurance

Announcement on Progress in Selling Partial Equity of Wholly-owned Subsidiary and Renewal of Business License by Subsidiary

Announcement on Convening the Q3 2024 Performance Briefing

Announcement on Voluntary Disclosure of Adding API Supplier for Albuvirtide for Injection and Subsidiary Sichuan Frontier Biopharmaceutical Co., Ltd. Passing Drug GMP Compliance Inspection

Announcement on Voluntary Disclosure on Obtaining Notice of Approval for Phase II Clinical Trials of Aikening's New Maintenance Treatment Indications

Report for Q3 2024

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2024

Announcement on Selling Partial Equity of Wholly-owned Subsidiaries and Passively Forming External Loans and Guarantees

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2024

Announcement on Using Temporarily Idle Raised Funds for Cash Management